Combination Immunotherapy with Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2 Expressing Breast Cancer Patients to Prevent Recurrence
ID Number 15-1098Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to test the HER2/neu peptide (piece of the protein) E75 as a vaccine in combination with Herceptin (trastuzumab) to determine if it can prevent breast cancer recurrence; to look at the immune system's response to the vaccine in combination with Herceptin; to collect information on the vaccine in combination with Herceptin's safety and dosing.
Recruiting Patients: Yes